Generic Name and Formulations:
Amlodipine (as besylate), benazepril (as HCl); 2.5mg/10mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 10mg/20mg, 10mg/40mg; caps.
Novartis Pharmaceuticals Corp
Indications for LOTREL:
Hypertension (not for initial therapy).
For patients not adequately controlled with amlodipine or benazepril monotherapy or in those who show inability to achieve BP control with amlodipine without developing edema: initially 2.5mg/10mg once daily; may titrate up to 10mg/40mg once daily if BP remains uncontrolled. Replacement therapy: may be substituted for titrated components. CrCl ≤30mL/min: not recommended. Hepatic impairment, elderly: consider lower doses.
History of ACEI-associated or other angioedema. Concomitant aliskiren in patients with diabetes. Concomitant neprilysin inhibitor (eg, sacubitril); do not give within 36hrs of switching to or from sacubitril/valsartan.
Fetal toxicity may develop; discontinue if pregnancy is detected. Salt/volume depletion. Renal or hepatic impairment. Dialysis (esp. high-flux membrane). Renal artery stenosis. CHF. Severe obstructive coronary artery disease. Severe aortic or mitral stenosis. Obstructive hypertrophic cardiomyopathy. Diabetes. Surgery. Discontinue if angioedema, laryngeal edema, jaundice or marked elevation in liver enzymes occurs. Monitor BP, electrolytes and renal function. Black patients may have higher risk of angioedema than non-black patients. Neonates. Elderly. Neonates. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.
Calcium channel blocker (CCB) (dihydropyridine) + ACE inhibitor.
See Contraindications. Increased risk of angioedema with concomitant neprilysin inhibitor or mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely, in general, avoid combined use of RAS inhibitors. Avoid aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K+supplements, K+ -sparing diuretics, or salt substitutes. May increase lithium levels; monitor. Potentiates simvastatin (max 20mg daily). Potentiated by diuretics, CYP3A4 inhibitors. Nitritoid reactions with concomitant injectable gold (sodium aurothiomalate); rare. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). Hypoglycemia with insulin and oral antidiabetics; rare.
Cough, edema, fatigue, dizziness, GI upset, angioedema, hypotension, hyperkalemia, palpitations, flushing, anaphylactoid reactions; rare: hepatic failure.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction